JAZZ Jazz Pharmaceuticals PLC

$123.11

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 8/22/2025

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.

Website: https://www.jazzpharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1232524
Address
FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD, DUBLIN, IE
Valuation
Market Cap
$6.24B
P/E Ratio
11.88
PEG Ratio
0.32
Price to Book
1.52
Performance
EPS
$8.65
Dividend Yield
Profit Margin
13.80%
ROE
14.30%
Technicals
50D MA
$128.48
200D MA
$118.45
52W High
$148.06
52W Low
$95.49
Fundamentals
Shares Outstanding
61M
Target Price
$192.22
Beta
0.42

JAZZ EPS Estimates vs Actual

Estimated
Actual

JAZZ News & Sentiment

Aug 21, 2025 • Zacks Commentary SOMEWHAT-BULLISH
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.
Aug 19, 2025 • GlobeNewswire NEUTRAL
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Aug 19, 2025 • Benzinga NEUTRAL
Zymeworks Announces Participation in Upcoming Investor Conferences - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
Aug 13, 2025 • Benzinga NEUTRAL
Onco360 adds Modeyso™ ( dordaviprone ) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ ( dordaviprone ) .
Aug 12, 2025 • Benzinga NEUTRAL
Artios Pharma Appoints Michael T. Andriole as CEO and Director to Advance Alnodesertib ( ART0380 ) into Late-stage Development
Mike Andriole brings approximately 25 years of experience in the biopharmaceutical industry and a successful track record of delivering new first-in-class oncology therapies in indications of high unmet need to patients where no approved treatment exists
Aug 11, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Sentiment Snapshot

Average Sentiment Score:

0.075
50 articles with scored sentiment

Overall Sentiment:

Neutral

JAZZ Reported Earnings

Feb 25, 2025
Dec 31, 2024 (Post market)
0.79 Surprise
  • Reported EPS: $6.60
  • Estimate: $5.81
  • Whisper:
  • Surprise %: 13.6%
Nov 06, 2024
Sep 30, 2024 (Post market)
1.11 Surprise
  • Reported EPS: $6.61
  • Estimate: $5.50
  • Whisper:
  • Surprise %: 20.2%
Jul 31, 2024
Jun 30, 2024 (Post market)
0.53 Surprise
  • Reported EPS: $5.30
  • Estimate: $4.77
  • Whisper:
  • Surprise %: 11.1%
May 01, 2024
Mar 31, 2024 (Post market)
-1.5 Surprise
  • Reported EPS: $2.68
  • Estimate: $4.18
  • Whisper:
  • Surprise %: -35.9%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.16 Surprise
  • Reported EPS: $5.02
  • Estimate: $5.18
  • Whisper:
  • Surprise %: -3.1%
Nov 08, 2023
Sep 30, 2023 (Post market)
-0.09 Surprise
  • Reported EPS: $4.84
  • Estimate: $4.93
  • Whisper:
  • Surprise %: -1.8%
Aug 09, 2023
Jun 30, 2023 (Post market)
0.08 Surprise
  • Reported EPS: $4.51
  • Estimate: $4.43
  • Whisper:
  • Surprise %: 1.8%
May 10, 2023
Mar 31, 2023 (Post market)
-0.29 Surprise
  • Reported EPS: $3.95
  • Estimate: $4.24
  • Whisper:
  • Surprise %: -6.8%
Mar 01, 2023
Dec 31, 2022 (Post market)
-0.39 Surprise
  • Reported EPS: $-0.07
  • Estimate: $0.32
  • Whisper:
  • Surprise %: -121.9%

Financials